Special Issue

Bioactive Lipids in Disease: Diagnosis, Prognosis, and Pathophysiology

Message from the Guest Editor

Bioactive lipids represent an exceptionally diverse and potent class of signaling molecules that regulate a vast array of biological processes. A deeper understanding of these lipids is fundamental to unraveling the mechanisms underlying numerous human diseases, including metabolic disorders, cardiovascular diseases, cancer, and neurodegenerative conditions. Their dynamic levels in blood and other biofluids can reflect underlying pathological states, offering powerful tools for early diagnosis, patient stratification, prognostic assessment, and therapeutic response monitoring.

Despite substantial progress in lipidomics research, a significant proportion of bioactive lipids remains uncharacterized. The integration of advanced analytical methodologies presents opportunities for the discovery and functional characterization of novel bioactive lipid entities.

This Special Issue welcomes research contributions that enhance our understanding of bioactive lipids in disease, including studies on disease mechanisms, biomarker identification, therapeutic applications, and new methodological developments in lipid research.

Guest Editor

Dr. Xu Zhang

School of Basic Medical Sciences, Peking University, Beijing, China

Deadline for manuscript submissions

31 January 2026

MDPI

Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).